A review of recent regulatory filings indicates significant director activity at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Specifically, the company's director, Suliman Shehnaaz, recently sold a substantial block of common stock shares. According to disclosures filed with the SEC, this transaction took place on May 18, 2026.
The sale constituted the disposition of 5,740 shares of RARE’s common stock, totaling $144,188 at the time of the transaction. The reported execution price for these shares was $25.12 per share. It is noteworthy that this selling activity occurred when the stock was trading at $24.18, which represented a decline from the previous closing price of $25.00.
In other significant equity movements recorded within the same timeframe, Ms. Shehnaaz also received compensation in the form of restricted stock units (RSUs) and new stock options.
On May 14, 2026, she was awarded 7,751 RSUs under the company’s established 2023 Incentive Plan. These RSUs were acquired at a nominal price of $0.00 per share. The full vesting schedule for these units is set to occur on the earlier date between Ultragenyx's next Annual Meeting of Stockholders or May 14, 2027.
Furthermore, on that same date of May 14, 2026, she was granted an additional 14,058 stock options. These options carry an exercise price set at $25.80 per share and were initially acquired at a cost of $0.00 per share. The vesting period for these specific options is structured to complete on the earlier date between the company’s next Annual Meeting of Stockholders or May 14, 2027. These granted options also carry an expiration date set for May 14, 2036.
Following all reported transactions and grants, records indicate that Ms. Shehnaaz directly maintains a holding comprising 27,951 shares of Ultragenyx common stock, alongside the 14,058 stock options.
Company Financial Performance and Governance Updates
Beyond the individual director transactions, recent corporate announcements provided updates on RARE's financial standing and governance structure. For the first quarter of 2026, Ultragenyx Pharmaceutical Inc. released its financial results.
The company reported a net loss amounting to $1.84 per share for Q1 2026. This figure failed to meet consensus analyst expectations, which had projected a loss of $1.46 per share. Furthermore, the revenue generated by Ultragenyx was reported at $136 million. This revenue figure also fell short of the projected $160.69 million mark.
Despite these setbacks in both net loss and revenue compared to projections, the company did affirm its full-year revenue guidance for the period.
In matters of corporate governance, during an annual meeting of shareholders at Ultragenyx, three Class I directors were elected: Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch. These individuals will hold their seats until the 2029 annual meeting or until replacements are chosen.
The shareholder meeting also resulted in the approval of several key corporate proposals. The overall context provided by these financial results and director changes offers a comprehensive view of the company's current operational phase, alongside continued executive compensation activity.